January 6, 2016

Helix BioPharma Corp Signs License Agreement with Helix Polska to Develop Cancer Therapies in Poland (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” and listed on TSX & FSE: “HBP”) (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has granted a world-wide exclusive license for v-DOS47, an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2), to its wholly-owned subsidiary, Helix Polska.